Wednesday, April 17, 2013

Shenzen Chipscreen Bioscience announces positive topline Phase 2 data on Chidamide in refractory PTCL patients

Shenzhen Chipscreen Biosciences announced that Chidamide (Epidaza) met its primary endpoint in a Phase II trial, which was conducted in China patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The objective response rate was at least 27%, the agreed-upon goal. Chipscreen is developing the drug under an SFDA-approved accelerated review. The company will release more data at the ASCO conference in June.


Enter your email address:


Delivered by FeedBurner